Durect Share Price Today
(NASDAQ: DRRX)

Name: Durect Share Price Today (NASDAQ: DRRX) - Durect Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Durect share price is $0.77 & ₹66.97 as on 6 Mar 2025, 2.30 'hrs' IST

$0.77

▲

-0.02

(-2.41%)

Market is closed - opens 8 PM, 06 Mar 2025

View live Durect share price in Dollar and Rupees. Guide to invest in Durect stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Durect, along with analyst recommendations, forecasts, and comprehensive financials.

Durect share price movements

Today's Low: $0.75
Today's High: $0.85
$0.77
2.49%
Downside
Day's Volatility :11.67%
Upside
9.41%
52 Weeks Low: $0.70
52 Weeks High: $1.88
$0.77
8.96%
Downside
52 Weeks Volatility :62.71%
Upside
59.04%

Durect (DRRX) Returns

Period	Durect Corp	Russel 2000	Index (Russel 2000)
3 Months	-0.53%	0.0%	0.0%
6 Months	-52.41%	0.0%	0.0%
1 Year	-21.14%	0.0%	0.0%
3 Years	-86.71%	-11.6%	-11.6%

Durect (DRRX) Key Statistics

in dollars & INR

Previous Close	$0.79
Open	$0.79
Today's High	$0.85
Today's Low	$0.7508
Market Capitalization	$23.9M
Today's Volume	$35.9K
52 Week High	$1.88
52 Week Low	$0.701
Revenue TTM	$8.6M
EBITDA	$-19.4M
Earnings Per Share (EPS)	$-0.64
Profit Margin	-198.62%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-218.51%

How to invest in Durect Stock (DRRX) from India?

It is very easy for Indian residents to invest directly in Durect from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Durect stock in both Indian Rupees (INR) and US Dollars (USD). Search for Durect or DRRX on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Durect or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Durect shares which would translate to 1.129 fractional shares of Durect as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Durect, in just a few clicks!

Returns in Durect (DRRX) for Indian investors in Rupees

The Durect stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

Durect investment value today

Current value as on today

₹83,520

Returns

₹16,480

(-16.48%)

Returns from Durect Stock

₹21,429 (-21.43%)

Dollar Returns

₹4,949 (+4.95%)

Indian investors sentiment towards Durect (DRRX)

-24%

Period: Feb 3, 2025 to Mar 5, 2025. Change in 30 Days versus previous period

Search interest for Durect Stock from India on INDmoney has decreased by -24% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Durect

Ingalls & Snyder LLC
5.12%
Richmond Brothers Inc
4.13%
Vanguard Group Inc
3.67%
Gagnon Securities LLC
1.30%
Geode Capital Management, LLC
1.06%
Beirne Wealth Consulting Services, LLC
1.05%

Analyst Recommendation on Durect

Buy

70%Buy

30%Hold

0%Sell

Based on 10 Wall street analysts offering stock ratings for Durect(by analysts ranked 0 to 5 stars)

Based on 10 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Durect Stock (DRRX)

What analysts predicted

Upside of 776.62%

Target:

$6.75

Current:

$0.77

Insights on Durect Stock (Ticker Symbol: DRRX)

Price Movement
In the last 6 months, DRRX stock has moved down by -50.9%
Decreasing Revenue
Revenue is down for the last 2 quarters, 2.17M → 1.92M (in $), with an average decrease of 11.2% per quarter
Decreasing Net Profit
Netprofit is down for the last 2 quarters, -3.7M → -4.28M (in $), with an average decrease of 15.8% per quarter
DRRX vs ITCI (1 yr)
In the last 1 year, Intra-cellular Therapies, Inc. has given 98.7% return, outperforming this stock by 119.8%
DRRX vs ITCI (3 yr)
In the last 3 years, Intra-cellular Therapies, Inc. has given 138.1% return, outperforming this stock by 225.6%
Price to Sales
ForDRRX every $1 of sales, investors are willing to pay $2.7, whereas for Intra-cellular Therapies, Inc., the investors are paying $19.9 for every $1 of sales.

DRRX Durect Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$18.6M	↓ 62.25%
Net Income	$-25.3M	↑ 585.3%
Net Profit Margin	-136.4%	↓ 128.89%

	FY19	Y/Y Change
Revenue	$29.6M	↑ 59.25%
Net Income	$-22.8M	↓ 10.01%
Net Profit Margin	-77.08%	↑ 59.32%

	FY20	Y/Y Change
Revenue	$30.1M	↑ 1.85%
Net Income	$-2.5M	↓ 88.93%
Net Profit Margin	-8.38%	↑ 68.7%

	FY21	Y/Y Change
Revenue	$14.0M	↓ 53.58%
Net Income	$-38.1M	↑ 1411.7%
Net Profit Margin	-272.77%	↓ 264.39%

	FY22	Y/Y Change
Revenue	$19.3M	↑ 37.96%
Net Income	$-35.6M	↓ 6.66%
Net Profit Margin	-184.54%	↑ 88.23%

	FY23	Y/Y Change
Revenue	$8.5M	↓ 55.67%
Net Income	$-27.6M	↓ 22.37%
Net Profit Margin	-323.16%	↓ 138.62%

	Q2 FY23	Q/Q Change
Revenue	$2.1M	↑ 1.31%
Net Income	$-11.2M	↓ 8.55%
Net Profit Margin	-537.29%	↑ 57.94%

	Q3 FY23	Q/Q Change
Revenue	$1.7M	↓ 16.19%
Net Income	$-3.0M	↓ 73.03%
Net Profit Margin	-172.88%	↑ 364.41%

	Q4 FY23	Q/Q Change
Revenue	$2.7M	↑ 53.04%
Net Income	$-1.4M	↓ 52.21%
Net Profit Margin	-53.99%	↑ 118.89%

	Q1 FY24	Q/Q Change
Revenue	$1.8M	↓ 31.55%
Net Income	$-7.6M	↑ 430.4%
Net Profit Margin	-418.34%	↓ 364.35%

	Q2 FY24	Q/Q Change
Revenue	$2.2M	↑ 18.83%
Net Income	$-3.7M	↓ 51.59%
Net Profit Margin	-170.43%	↑ 247.91%

	Q3 FY24	Q/Q Change
Revenue	$1.9M	↓ 11.24%
Net Income	$-4.3M	↑ 15.81%
Net Profit Margin	-222.37%	↓ 51.94%

	FY18	Y/Y Change
Profit	$14.3M	↓ 66.38%

	FY19	Y/Y Change
Profit	$25.4M	↑ 77.76%

	FY20	Y/Y Change
Profit	$28.7M	↑ 12.92%

	FY21	Y/Y Change
Profit	$12.0M	↓ 58.12%

	FY22	Y/Y Change
Profit	$17.7M	↑ 47.19%

	FY23	Y/Y Change
Profit	$6.8M	↓ 61.4%

	Q2 FY23	Q/Q Change
Profit	$1.7M	↑ 3.36%

	Q3 FY23	Q/Q Change
Profit	$1.4M	↓ 16.84%

	Q4 FY23	Q/Q Change
Profit	$2.0M	↑ 40.43%

	Q1 FY24	Q/Q Change
Profit	$1.5M	↓ 23.52%

	Q2 FY24	Q/Q Change
Profit	$1.8M	↑ 18.01%

	Q3 FY24	Q/Q Change
Profit	$1.4M	↓ 22.09%

	FY18	Y/Y Change
Operating Cash Flow	$-19.8M	↑ 1370.59%
Investing Cash Flow	$4.5M	↓ 64.25%
Financing Cash Flow	$17.5M	↑ 38.48%

	FY19	Y/Y Change
Operating Cash Flow	$11.1M	↓ 156.21%
Investing Cash Flow	$-27.3M	↓ 702.25%
Financing Cash Flow	$19.5M	↑ 11.56%

	FY20	Y/Y Change
Operating Cash Flow	$-38.7M	↓ 448.65%
Investing Cash Flow	$9.4M	↓ 134.52%
Financing Cash Flow	$15.7M	↓ 19.7%

	FY21	Y/Y Change
Operating Cash Flow	$-37.3M	↓ 3.6%
Investing Cash Flow	$15.3M	↑ 62.33%
Financing Cash Flow	$50.5M	↑ 222.68%

	FY22	Y/Y Change
Operating Cash Flow	$-26.3M	↓ 29.57%
Investing Cash Flow	$19.8M	↑ 29.55%
Financing Cash Flow	$83.0K	↓ 99.84%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$-9.3M	↑ 0.86%
Investing Cash Flow	$1.8M	↓ 137.39%
Financing Cash Flow	$-34.0K	↓ 100.34%

Durect Technicals Summary

Sell

Neutral

Buy

Durect is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Durect (DRRX) Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Durect Corp	0.17%	-52.41%	-21.14%	-86.71%	-96.05%
Intra-cellular Therapies, Inc.	3.38%	81.15%	98.68%	146.46%	588.66%
Haleon Plc Spon Ads	10.71%	2.13%	26.53%	42.24%	42.24%
Zoetis Inc.	-3.04%	-10.5%	-9.01%	-11.21%	28.74%
Neurocrine Biosciences Inc.	-25.31%	-6.07%	-13.91%	29.45%	28.72%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Durect Corp	NA	NA	-0.46	-0.5	-2.19	-0.31	NA	0.04
Intra-cellular Therapies, Inc.	NA	NA	0.0	0.13	-0.09	-0.07	NA	10.81
Haleon Plc Spon Ads	26.35	26.35	1.92	0.36	0.09	0.04	0.02	1.8
Zoetis Inc.	31.17	31.17	3.01	6.07	0.51	0.15	0.01	10.64
Neurocrine Biosciences Inc.	34.6	34.6	0.27	6.44	0.14	0.1	NA	26.05

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Durect Corp	Buy	$23.9M	-96.05%	NA	-198.62%
Intra-cellular Therapies, Inc.	Buy	$14.0B	588.66%	NA	-10.97%
Haleon Plc Spon Ads	Buy	$47.7B	42.24%	26.35	12.84%
Zoetis Inc.	Buy	$76.1B	28.74%	31.17	26.86%
Neurocrine Biosciences Inc.	Buy	$11.4B	28.72%	34.6	14.49%

About Durect

DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. It also offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine over three days in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in other countries. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Innocoll Pharmaceuticals Limited. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.

Organization	Durect
Employees	46
CEO	Dr. James E. Brown D.V.M.
Industry	Health Technology

Management People of Durect

Name	Title
Dr. James E. Brown D.V.M.	Co-Founder, CEO, President & Director
Mr. Timothy M. Papp M.B.A.	CFO & Secretary
Dr. Norman L. Sussman M.D.	Chief Medical Officer
Ms. Judy R. Joice	Senior Vice President of Operations & Corporate Quality Assurance
Dr. WeiQi Lin M.D., Ph.D.	Executive VP of Research & Development and Principal Scientist
Ms. Jian Li M.B.A.	Senior VP of Finance, Corporate Controller & Secretary
Dr. Su Il Yum Ph.D.	Executive Officer

Important FAQs about investing in DRRX Stock from India :

What is Durect share price today?

Durect share price today stands at $0.77, Open: $0.79 ; Previous Close: $0.79 ; High: $0.85 ; Low: $0.75 ; 52 Week High: $1.88 ; 52 Week Low: $0.70.

The stock opens at $0.79, after a previous close of $0.79. The stock reached a daily high of $0.85 and a low of $0.75, with a 52-week high of $1.88 and a 52-week low of $0.70.

Can Indians buy Durect shares?

Yes, Indians can invest in the Durect (DRRX) from India.

With INDmoney, you can buy Durect at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Durect at zero transaction cost.

How can I buy Durect shares from India?

It is very easy to buy Durect from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Durect (DRRX) be purchased?

Yes, you can buy fractional shares of Durect with INDmoney app.

What are the documents required to start investing in Durect stocks?

To start investing in Durect, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.